151 related articles for article (PubMed ID: 18379939)
41. Management of primary intraocular lymphoma.
Kim SK; Chan CC; Wallace DJ
Curr Oncol Rep; 2005 Jan; 7(1):74-9. PubMed ID: 15610690
[TBL] [Abstract][Full Text] [Related]
42. Repeated IL-10 measurement in aqueous humor and OCT imaging are valuable tools to monitor intraocular lymphoma treated with intravitreal injections of methotrexate.
Saleh M; Nikolitch K; Bourcier T; Speeg C; Gaucher D
Graefes Arch Clin Exp Ophthalmol; 2012 May; 250(5):761-4. PubMed ID: 21755434
[No Abstract] [Full Text] [Related]
43. Membrane transport of folates.
Matherly LH; Goldman DI
Vitam Horm; 2003; 66():403-56. PubMed ID: 12852262
[TBL] [Abstract][Full Text] [Related]
44. Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and-resistant leukemia cells.
Jansen G; Mauritz RM; Assaraf YG; Sprecher H; Drori S; Kathmann I; Westerhof GR; Priest DG; Bunni M; Pinedo HM; Schornagel JH; Peters GJ
Adv Enzyme Regul; 1997; 37():59-76. PubMed ID: 9381986
[TBL] [Abstract][Full Text] [Related]
45. [Initial experience of treatment of primary intraocular lymphomas associated with primary CNS lymphomas].
Tropinskaia OF; Grishina EE; Serova NK; Kobiakov GL; Aronov MS; Shishkina LV
Zh Vopr Neirokhir Im N N Burdenko; 2012; 76(4):19-25; discussion 25. PubMed ID: 23033588
[TBL] [Abstract][Full Text] [Related]
46. Intraocular rituximab.
Singh AD; Peereboom DM
Eye (Lond); 2007 Dec; 21(12):1453-4. PubMed ID: 18159211
[No Abstract] [Full Text] [Related]
47. Maculopathy in patients with primary CNS lymphoma treated with chemotherapy in conjunction with blood-brain barrier disruption.
Vicuna-Kojchen J; Frenkel S; Siegal T; Shalom E; Chowers I; Pe'er J
Br J Ophthalmol; 2008 Feb; 92(2):231-5. PubMed ID: 18227203
[TBL] [Abstract][Full Text] [Related]
48. Clinical outcomes of primary intraocular lymphoma patients treated with front-line systemic high-dose methotrexate and intravitreal methotrexate injection.
Ma WL; Hou HA; Hsu YJ; Chen YK; Tang JL; Tsay W; Yeh PT; Yang CM; Lin CP; Tien HF
Ann Hematol; 2016 Mar; 95(4):593-601. PubMed ID: 26732884
[TBL] [Abstract][Full Text] [Related]
49. Despite some expression of folate receptor alpha in human mesothelioma cells, internalization of methotrexate is predominantly carrier mediated.
Khokhar NZ; Lam AF; Rusch VW; Sirotnak FM
J Thorac Cardiovasc Surg; 2002 May; 123(5):862-8. PubMed ID: 12019370
[TBL] [Abstract][Full Text] [Related]
50. Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy.
Berenbom A; Davila RM; Lin HS; Harbour JW
Eye (Lond); 2007 Sep; 21(9):1198-201. PubMed ID: 16732210
[TBL] [Abstract][Full Text] [Related]
51. Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: a Children's Cancer Group Study.
Levy AS; Sather HN; Steinherz PG; Sowers R; La M; Moscow JA; Gaynon PS; Uckun FM; Bertino JR; Gorlick R;
J Pediatr Hematol Oncol; 2003 Sep; 25(9):688-95. PubMed ID: 12972803
[TBL] [Abstract][Full Text] [Related]
52. Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis.
Wolf J; Stranzl T; Filipits M; Pohl G; Pirker R; Leeb B; Smolen JS
Ann Rheum Dis; 2005 Apr; 64(4):564-8. PubMed ID: 15345497
[TBL] [Abstract][Full Text] [Related]
53. Functional aspects of membrane folate receptors in human breast cancer cells with transport-related resistance to methotrexate.
Pinard MF; Jolivet J; Ratnam M; Kathmann I; Molthoff C; Westerhof R; Schornagel JH; Jansen G
Cancer Chemother Pharmacol; 1996; 38(3):281-8. PubMed ID: 8646804
[TBL] [Abstract][Full Text] [Related]
54. Determinants of the disparate antitumor effects of (6R)5,10-dideaza-5,6,7,8- tetrahydrofolate and methotrexate toward methotrexate resistant CCRF-CEM cells, characterized by severely impaired antifolate membrane transport.
Matherly LH; Angeles SM
Adv Exp Med Biol; 1993; 338():783-6. PubMed ID: 8304229
[No Abstract] [Full Text] [Related]
55. The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate.
Yang R; Kolb EA; Qin J; Chou A; Sowers R; Hoang B; Healey JH; Huvos AG; Meyers PA; Gorlick R
Clin Cancer Res; 2007 May; 13(9):2557-67. PubMed ID: 17473184
[TBL] [Abstract][Full Text] [Related]
56. Decreased expression of transporters reduces folate uptake across renal absorptive surfaces in experimental alcoholism.
Hamid A; Kaur J
J Membr Biol; 2007 Dec; 220(1-3):69-77. PubMed ID: 18008023
[TBL] [Abstract][Full Text] [Related]
57. Toxic corneal epitheliopathy after intravitreal methotrexate and its treatment with oral folic acid.
Gorovoy I; Prechanond T; Abia M; Afshar AR; Stewart JM
Cornea; 2013 Aug; 32(8):1171-3. PubMed ID: 23676783
[TBL] [Abstract][Full Text] [Related]
58. Effects of folate receptor expression following stable transfection into wild type and methotrexate transport-deficient ZR-75-1 human breast cancer cells.
Dixon KH; Mulligan T; Chung KN; Elwood PC; Cowan KH
J Biol Chem; 1992 Nov; 267(33):24140-7. PubMed ID: 1429743
[TBL] [Abstract][Full Text] [Related]
59. Rat reduced-folate carrier-1 is localized basolaterally in MDCK kidney epithelial cells and contributes to the secretory transport of methotrexate and fluoresceinated methotrexate.
Kneuer C; Honscha KU; Honscha W
Cell Tissue Res; 2005 Jun; 320(3):517-24. PubMed ID: 15846510
[TBL] [Abstract][Full Text] [Related]
60. Intraocular involvement is associated with a high risk of disease relapse in primary central nervous system lymphoma.
Zhuang L; Lai J; Chen K; Ding T; Yuan Y; Ma Y; Kang H; Lin Z; Fan N; Ma J; Zeng Q; Xu X; Wang Q; Chen B
Oncol Rep; 2019 Jan; 41(1):397-404. PubMed ID: 30320386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
